Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer

NCT00079040 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

65

Enrollment

NIH

Sponsor class

Conditions

Extensive Stage Small Cell Lung Cancer

Interventions

DRUG: cisplatin
DRUG: etoposide
BIOLOGICAL: bevacizumab
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)